The test-negative design for the estimation of COVID-19 vaccine effectiveness: design evaluation and development of statistical methods in the evolving context

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 462230

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2022
  • Known Financial Commitments (USD)

    $214,745.05
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Schnitzer Mireille E, Talbot Denis
  • Research Location

    Canada
  • Lead Research Institution

    Université de Montréal
  • Research Priority Alignment

    N/A
  • Research Category

    Epidemiological studies

  • Research Subcategory

    Impact/ effectiveness of control measures

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Fast research designs have been proposed for estimating how well different vaccines protect against disease, severe disease, hospitalization, and death from COVID-19. In fact, ongoing study is needed to evaluate different levels of vaccination (2 doses, boosters, different lags between doses, etc) in terms of how well they protect against illness, which may vary depending on the current circulation of virus variants. These fast designs typically involve identifying people who have been tested for COVID-19, often at a test-site or in a hospital. An established design is called the "test-negative design" which specifically involves identifying people who have symptoms associated with the disease in question and who then get tested. Scientists can estimate vaccine effectiveness by comparing people who test positive to people who test negative. If the negatives have higher rates of vaccination, this will indicate effectiveness of the vaccine. But, depending on how the design and statistical methods are applied, there may be bias in the estimation of effectiveness. Our research team has recently noted that, because of challenges of how test data are collected in our healthcare systems across Canada, the classical version of the test-negative design cannot always be applied. For example, some designs have used all test data, rather than only data from those who have certain symptoms. We are interested in evaluating how much bias can be caused by this difference in design, and identifying scenarios in which this can create misleading results. Secondly, we are interested in developing statistical methods that can address the limitations of the regression approach that is essentially the only one currently being used. We will identify limitations of current methods and propose new (or adapted) methods that can address these limitations. Our goal is to produce more reliable statistical methods so that we can improve our monitoring of the benefits of vaccination.